ClinicalTrials.gg
CompletedNCT03963401Updated Aug 4, 2021Results posted

A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis

A Phase 2 interventional study of PF-06700841 and Placebo in Psoriatic Arthritis, sponsored by Pfizer. Completed at 48 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-08-04.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
219
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies in Arthritis, Psoriatic by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Psoriatic · Pfizer.

Enrollment
6th of 10
219 · median 307
Started
2019
with 1 other
Phase 2
Only one
of the 29
Registered
25th of 29
by date

Among the 29 studies in Arthritis, Psoriatic by Pfizer, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2019, is the only one in phase 2, and was the 25th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

1 of the 29 studies in Arthritis, Psoriatic by Pfizer is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Arthritis, Psoriatic by Pfizer, or all of them as a file.
02

Study summary

This is a 52 week Phase 2b study designed to evaluate the efficacy at 16 weeks and to evaluate the safety and efficacy up to 1 year in subjects with active psoriatic arthritis.

03

Conditions studied

  • Psoriatic Arthritis

Keywords

  • Spondyloarthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active arthritis at screening/baseline as indicated by >/= 3 tender/painful and 3 swollen joints.
  • Active plaque psoriasis at screening and baseline.

Exclusion criteria

Exclusion Criteria:

  • Non-plaque forms of psoriasis (with exception of nail psoriasis).
  • History of rheumatic disease other than PsA; also prior history of or current, rheumatic inflammatory disease other than PsA.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
219 participants (actual)

Study arms

  • Experimental
    PF-06700841 60 mg once daily

    PF-06700841 60 mg once daily for 52 weeks

    Drug: PF-06700841

  • Experimental
    PF-06700841 30 mg once daily

    PF-06700841 30 mg once daily for 52 weeks

    Drug: PF-06700841

  • Experimental
    PF-06700841 10 mg once daily followed by 60 mg once daily

    PF-06700841 10 mg once daily for 16 weeks, followed by 60 mg once daily until Week 52

    Drug: PF-06700841

  • Experimental
    PF-06700841 10 mg once daily followed by 30 mg once daily

    PF-06700841 10 mg once daily for 16 weeks, followed by 30 mg once daily until Week 52

    Drug: PF-06700841

  • Placebo comparator
    Placebo once daily followed by 60 mg once daily

    Placebo once daily for 16 weeks, followed by PF-06700841 60 mg once daily until Week 52

    Other: Placebo

  • Placebo comparator
    Placebo once daily followed by 30 mg once daily

    Placebo once daily for 16 weeks, followed by PF-06700841 30 mg once daily until Week 52

    Other: Placebo

Interventions

  • Starting after the Week 16 visit, subjects receiving PF-06700841 10 mg once daily will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.

  • OtherPlacebo

    Starting after the Week 16 visit, subjects receiving placebo will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving an American College of Rheumatology 20 (ACR20) Response at Week 16

    ACR 20 was calculated as a ≥20% improvement in tender and swollen joint counts and ≥20% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level). The participants receiving placebo in the initial period (Day 1 - Week 16) were combined into a single placebo group, while those who received PF-06700841 (10 mg QD) in the initial period were combined into a single PF-06700841 10 mg QD group.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving an ACR20 Response at Week 16 in the Subgroup of Participants Who Were Tumor Necrosis Factor (TNF) α Inhibitor naïve

    ACR 20 was calculated as a ≥20% improvement in tender and swollen joint counts and ≥20% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level). The participants receiving placebo in the initial period (Day 1 - Week 16) were combined into a single placebo group, while those who received PF-06700841 (10 mg QD) in the initial period were combined into a single PF-06700841 10 mg QD group.

    Time frame: Week 16

  2. Percentage of Participants Achieving an ACR20 Response at Weeks 2, 4, 8, 12, 20, 28, 36, 44 and 52

    The American College of Rheumatology's definition for calculating improvement in rheumatoid arthritis (ACR20) was calculated as a ≥20% improvement in tender and swollen joint counts and ≥20% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level).

    Time frame: Weeks 2, 4, 8, 12, 20, 28, 36, 44 and 52

  3. Percentage of Participants Achieving an ACR50 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

    The American College of Rheumatology's definition for calculating improvement in rheumatoid arthritis (ACR50) was calculated as a ≥50% improvement in tender and swollen joint counts and ≥50% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level).

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

  4. Percentage of Participants Achieving an ACR70 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

    The American College of Rheumatology's definition for calculating improvement in rheumatoid arthritis (ACR70) was calculated as a ≥70% improvement in tender and swollen joint counts and ≥70% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level).

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

  5. Change From Baseline in Tender/Painful Joint Count at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

    The tender/painful joints were assessed by a blinded assessor to determine the number of joints that were considered tender/painful using the following scale: Present/Absent/Not Done/Not Applicable (used for artificial or missing joints). Artificial joints was not assessed. Injected joints was counted according to their pre-injection status for the remainder of the study. The assessment was based on 68 joints. The score range was 0 to 68, with a higher score indicating a greater degree of tenderness. A negative change from baseline represents improvement.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

  6. Change From Baseline in Swollen Joint Count at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

    The swollen joints were assessed by a blinded assessor to determine the number of joints that were considered swollen using the following scale: Present/Absent/Not Done/Not Applicable (used for artificial or missing joints). Artificial joints was not assessed. Injected joints was counted according to their pre-injection status for the remainder of the study. The assessment was based on 66 joints. The score range was 0 to 66, with a higher score indicating a greater degree of swelling. A negative change from baseline represents improvement.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

  7. Change From Baseline in Patient's Assessment of Arthritis Pain at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

    Participants assessed the severity of their arthritis pain using a 100 millimeter (mm) visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain. VAS data was rescaled prior to any calculation and analysis. Rescaled VAS score (mm) = (100 mm) × (length at mark in mm/overall length of line in mm). The score range was 0 mm to 100 mm, with a higher score indicating a higher degree of pain. A negative change from baseline represents improvement.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

  8. Change From Baseline in Patient's Global Assessment of Arthritis at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

    Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?". The participant's response was recorded using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (very well) and 100 (very poorly). VAS data was rescaled prior to any calculation and analysis. Rescaled VAS score (mm) = (100 mm) × (length at mark in mm/overall length of line in mm). The score range was 0 mm to 100 mm, and a negative change from baseline represents improvement.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

  9. Change From Baseline in Physician's Global Assessment of Arthritis at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

    The blinded assessor assessed the participant's overall arthritis appears at the time of each visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (very good) and 100 (very poor). VAS data was rescaled prior to any calculation and analysis. Rescaled VAS score (mm) = (100 mm) × (length at mark in mm/overall length of line in mm). The score range was 0 mm to 100 mm, and a negative change from baseline represents improvement.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

  10. Change From Baseline in Health Assessment Questionnaire (HAQ) Disability Index (DI) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

    The HAQ-DI assessed the degree of difficulty a participant experienced in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question in the questionnaire, the level of difficulty is scored from 0 to 3 with 0 representing "no difficulty," 1 as "some difficulty," 2 as "much difficulty," and 3 as "unable to do". Any activity that requires assistance from another individual or requires the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range was 0 to 3, with a higher score indicating more difficulty in performing daily living activities. A negative change from baseline represents improvement.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

  11. Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

    C-reactive protein (hsCRP) is an acute phase reactant, which is indicative of inflammation and of its severity. Blood samples were obtained at Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52 for determination of hsCRP.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

  12. Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI 75) Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

    The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. Assessments of lesion Severity Score and Area Score are performed separately for each of the four body regions: head (including neck), upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). In each body region, the sum of the lesion Severity Scores for erythema, induration and scaling is multiplied by the Area Score which represents the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 indicates a 75% or greater reduction in PASI scores from baseline.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

  13. Percentage of Participants Achieving a PASI 90 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

    The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. Assessments of lesion Severity Score and Area Score are performed separately for each of the four body regions: head (including neck), upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). In each body region, the sum of the lesion Severity Scores for erythema, induration and scaling is multiplied by the Area Score which represents the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 indicates a 90% or greater reduction in PASI scores from baseline.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

  14. Percentage of Participants Achieving a PASI 100 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

    The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. Assessments of lesion Severity Score and Area Score are performed separately for each of the four body regions: head (including neck), upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). In each body region, the sum of the lesion Severity Scores for erythema, induration and scaling is multiplied by the Area Score which represents the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 100 indicates a 100% reduction in PASI scores from baseline.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

  15. Change From Baseline in the Enthesitis Score (Using the Spondyloarthritis Research Consortium of Canada [SPARCC] Enthesitis Index) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

    The SPARCC Enthesitis Index examines tenderness at sixteen sites: medial epicondyle humerus, lateral epicondyle humerus, supraspinatus insertion into greater tuberosity of humerus, greater trochanter, quadriceps insertion into superior border of patella, patellar ligament insertion into inferior pole of patella or tibial tubercle (considered 1 site for scoring purposes), Achilles tendon insertion into calcaneum and plantar fascia insertion into calcaneum. Each site is classified on a dichotomous basis as either tender (score=1) or not tender (score=0). The SPARCC Enthesitis Index scores range from 0-16, with higher scores indicating higher disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

  16. Change From Baseline in the Enthesitis Score (Using the Leeds Enthesitis Index) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

    The Leeds Enthesitis Index (LEI) examines tenderness at six sites: lateral epicondyle humerus, medial femoral condyle and Achilles tendon insertion. Each site is assessed as either tender (score=1) or not tender (score=0). The LEI scores range from 0-6, with higher scores indicating higher disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

  17. Change From Baseline in the Dactylitis Severity Score (DSS) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

    The number of digits in hands and feet with dactylitis was evaluated by a blinded assessor. In addition, dactylitis severity was scored based upon digit tenderness using a scale of 0-3, where 0 = no tenderness to 3 = extreme tenderness, in each digit of the hands and feet. The range of total dactylitis scores was 0-60, with higher scores indicating greater severity. A negative change from baseline represents improvement.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

  18. Change From Baseline in the Nail Psoriasis Severity Index (NAPSI) Score at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

    A target finger nail was evaluated by the blinded assessor using the NAPSI scale. At the baseline visit, the worst case fingernail was chosen and the same nail was evaluated consistently through the entire study. Each quadrant of the target nail was graded for nail matrix psoriasis (including any of the following parameters: pitting, leukonychia, red spots in lunula, nail plate crumbling) and nail bed psoriasis (including any of the following parameters: onycholysis, splinter hemorrhages, oil drop (salmon patch) discoloration, nail bed hyperkeratosis). The target nail NAPSI scores range from 0 to 8, with higher scores indicating higher disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

  19. Change From Baseline in the Patient's Global Joint and Skin Assessment-Visual Analog Scale (PGJS-VAS) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

    Participant's perception of disease was assessed using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (excellent) and 100 (poor). The rating corresponded to the way in which the participant felt over the past week in terms of how they were affected by their: 1) psoriasis and arthritis (global, PGA); 2) arthritis only (PJA) and 3) psoriasis only (PSA). Rescaled VAS score was used. Rescaled VAS score (mm) = (100 mm) × (length at mark in mm/overall length of line in mm). A negative change from baseline represents improvement.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

  20. Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

    The FACIT-F Scale is a patient completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue).

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

  21. Change From Baseline in the Short-Form-36 Health Survey (SF-36) Version 2, Acute at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52

    The SF-36 version 2 (Acute version) is a 36-item generic health status measure. It measures 8 general health concepts or domains: Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH). These 8 domains can also be summarized as physical and mental component scores. The summary component scores, Physical Component Summary (PCS) and Mental Component Summary (MCS), are based on a normalized sum of the 8 scale scores PF, RP, BP, GH, VT, SF, RE, and MH. All domains and summary components are scored such that a higher score indicates a higher functioning or health level. The minimum and maximum scores of the PCS Score are 22 and 59 respectively. The minimum and maximum scores of the MCS Score are 11 and 62 respectively.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52

  22. Percentage of Participants Achieving Minimal Disease Activity (MDA) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52

    A psoriatic arthritis participant was defined as having MDA response when 5 of the 7 following criteria were met: 1) tender joint count ≤1; 2) swollen joint count ≤1; 3) Psoriasis Area and Severity Index (quantifying the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area affected) score ≤1 or Body Surface Area (assessment of body surface area involved in psoriasis) ≤3%; 4) Patient's Assessment of Arthritis Pain (assessment of the patient's level of pain using a horizontal 100 mm visual analog scale) ≤15 mm; 5) Patient's Global Arthritis Assessment (patient's overall assessment of how the arthritis was doing by a 100 mm visual analog scale) ≤20 mm; 6) Health Assessment Questionnaire - Disability Index (assessment of the degree of difficulty a patient experienced) score ≤0.5; 7) tender entheseal points (assessment of tenderness using Leed's Enthesitis Index) ≤1.

    Time frame: Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52

  23. Percentage of Participants Achieving Very Low Disease Activity (VLDA) Response at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52

    A participant was in VLDA when all the 7 following criteria were met: 1) tender joint count ≤1; 2) swollen joint count ≤1; 3) Psoriasis Area and Severity Index (quantifying the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area affected) score ≤1 or Body Surface Area (assessment of body surface area involved in psoriasis) ≤3%; 4) Patient's Assessment of Arthritis Pain (assessment of the patient's level of pain using a horizontal 100 mm visual analog scale) ≤15 mm; 5) Patient's Global Arthritis Assessment (patient's overall assessment of how the arthritis was doing by a 100 mm visual analog scale) ≤20 mm; 6) Health Assessment Questionnaire - Disability Index (assessment of the degree of difficulty a patient experienced) score ≤0.5; 7) tender entheseal points (assessment of tenderness using Leed's Enthesitis Index) ≤1.

    Time frame: Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52

  24. Change From Baseline in the Disease Activity Index for Reactive Arthritis/PsA (DAREA/DAPSA) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52

    DAREA/DAPSA is a composite instrument to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender/painful joint count + swollen joint count (using SJC66/ TJC68 assessments), Patient's Global Assessment of Arthritis (PtGA in cm), Patient's Assessment of Arthritis Pain (PAIN in cm) and C-reactive protein (CRP) (in mg/dL). Since DAREA reflects domains found important in PsA, it has been proposed to serve as a Disease Activity Index for Psoriatic Arthritis (DAPSA). DAREA/DAPSA was calculated as follows: DAREA/DAPSA= SJC66 + TJC68 + PtGA + PAIN + CRP. A negative change from baseline represents improvement.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52

  25. Percentage of Participants Achieving the Psoriatic Arthritis Response Criteria (PsARC) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52

    The PsARC response was defined as improvement in two of the following 4 criteria, one of which must be joint pain or swelling, without worsening in any measure: (1) ≥20% improvement in Physician's Global Assessment of Arthritis (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity); (2) ≥20% improvement in Patient's Global Assessment of Arthritis (the patient's overall assessment of how the arthritis was doing by a visual analog scale); (3) ≥30% improvement in tender joint count (68); and (4) ≥30% improvement in swollen joint count.

    Time frame: Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52

  26. Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52

    PASDAS is a composite psoriatic arthritis disease activity score that includes the following components: patient's global joint and skin assessment (visual analog scale in mm), physician's global psoriatic arthritis assessment (visual analog scale in mm), swollen (66 joints) and tender joint counts (68 joints), Leeds Enthesitis Index score, tender dactylitic digit score, physical component summary score (PCS) of Short Form 36 Health Survey and C-reactive protein (mg/L). Any missing component would result in PASDAS as missing. A higher PASDAS score indicates a higher disease activity.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52

  27. Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) From Baseline (Day 1) Through Week 56 (All Causalities)

    Treatment-emergent AEs are those with initial onset or that worsen in severity after the first dose of the study medication. All AEs in the table below were treatment-emergent AEs. An SAE is any untoward medical occurrence at any dose that: results in death; is life threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect; or that is considered to be an important medical event that may jeopardize the participant or may require intervention to prevent one of the other AE outcomes. Severe AEs were defined as AEs that interfered significantly with participant's usual function. Both SAEs and severe AEs were according to the investigator's assessment.

    Time frame: Baseline (Day 1) through Week 56

  28. Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) From Baseline (Day 1) Through Week 56 (Treatment-related)

    Treatment-emergent AEs are those with initial onset or that worsen in severity after the first dose of the study medication. All AEs in the table below were treatment-emergent AEs. An SAE is any untoward medical occurrence at any dose that: results in death; is life threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect; or that is considered to be an important medical event that may jeopardize the participant or may require intervention to prevent one of the other AE outcomes. Severe AEs were defined as AEs that interfered significantly with participant's usual function. Both SAEs and severe AEs were according to the investigator's assessment. Treatment-related AEs were also determined by the investigator.

    Time frame: Baseline (Day 1) through Week 56

  29. Number of Participants Who Discontinued From Study Due to Treatment-emergent AEs From Baseline (Day 1) Through Week 56

    An AE is any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of the study medication.

    Time frame: Baseline (Day 1) through Week 56

07

Results

Posted Aug 4, 2021

Participant flow

Initial Period (Day 1 - Week 16)
Participant flow — Initial Period (Day 1 - Week 16)
MilestonePF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Started606116153433
Treated606016153433
Completed575714133131
Not completed342232
Withdrew: Adverse event120012
Withdrew: Lack of efficacy001100
Withdrew: Withdrawal by subject211120
Withdrew: Randomized but not treated010000
Extension Period (Week 17 - Week 52)
Participant flow — Extension Period (Week 17 - Week 52)
MilestonePF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Started575714133131
Completed435210122526
Not completed1454165
Withdrew: Adverse event632043
Withdrew: Lack of efficacy101000
Withdrew: Lost to follow-up001000
Withdrew: Non-compliance with study drug100000
Withdrew: Withdrawal by subject410011
Withdrew: No longer meets eligibility criteria100000
Withdrew: Other110111

Outcome measures

PrimaryPercentage of Participants Achieving an American College of Rheumatology 20 (ACR20) Response at Week 16

ACR 20 was calculated as a ≥20% improvement in tender and swollen joint counts and ≥20% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level). The participants receiving placebo in the initial period (Day 1 - Week 16) were combined into a single placebo group, while those who received PF-06700841 (10 mg QD) in the initial period were combined into a single PF-06700841 10 mg QD group.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an American College of Rheumatology 20 (ACR20) Response at Week 16
Percentage of participantsPlaceboPF-06700841 10 mg QDPF-06700841 30 mg QDPF-06700841 60 mg QD
Percentage of Participants Achieving an American College of Rheumatology 20 (ACR20) Response at Week 1643.28 (31.42 to 55.15)64.52 (47.67 to 81.36)66.67 (54.74 to 78.59)74.58 (63.47 to 85.69)
Statistical analysis
  • Placebo vs PF-06700841 10 mg QD · Normal approximation, Dunnett's method · p = 0.1172 · Mean difference (final values): 21.23 · 90% CI 3.94 to 38.52
  • Placebo vs PF-06700841 30 mg QD · Normal approximation, Dunnett's Method · p = 0.0197 · Median difference (final values): 23.38 · 90% CI 9.26 to 37.50
  • Placebo vs PF-06700841 60 mg QD · Normal approximation, Dunnett's Method · p = 0.0006 · Median difference (final values): 31.29 · 90% CI 17.65 to 44.93
SecondaryPercentage of Participants Achieving an ACR20 Response at Week 16 in the Subgroup of Participants Who Were Tumor Necrosis Factor (TNF) α Inhibitor naïve

ACR 20 was calculated as a ≥20% improvement in tender and swollen joint counts and ≥20% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level). The participants receiving placebo in the initial period (Day 1 - Week 16) were combined into a single placebo group, while those who received PF-06700841 (10 mg QD) in the initial period were combined into a single PF-06700841 10 mg QD group.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an ACR20 Response at Week 16 in the Subgroup of Participants Who Were Tumor Necrosis Factor (TNF) α Inhibitor naïve
Percentage of participantsPlaceboPF-06700841 10 mg QDPF-06700841 30 mg QDPF-06700841 60 mg QD
Percentage of Participants Achieving an ACR20 Response at Week 16 in the Subgroup of Participants Who Were Tumor Necrosis Factor (TNF) α Inhibitor naïve43.33 (30.79 to 55.87)64.29 (46.54 to 82.03)69.64 (57.60 to 81.69)74.55 (63.03 to 86.06)
Statistical analysis
  • Placebo vs PF-06700841 10 mg QD · Normal approximation method · p = 0.0588 · Mean difference (final values): 20.95 · 90% CI 2.72 to 39.19
  • Placebo vs PF-06700841 30 mg QD · Normal approximation method · p = 0.0030 · Median difference (final values): 26.31 · 90% CI 11.72 to 40.90
  • Placebo vs PF-06700841 60 mg QD · Normal approximation method · p = 0.0003 · Median difference (final values): 31.21 · 90% CI 16.93 to 45.50
SecondaryPercentage of Participants Achieving an ACR20 Response at Weeks 2, 4, 8, 12, 20, 28, 36, 44 and 52

The American College of Rheumatology's definition for calculating improvement in rheumatoid arthritis (ACR20) was calculated as a ≥20% improvement in tender and swollen joint counts and ≥20% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level).

Time frame:
Weeks 2, 4, 8, 12, 20, 28, 36, 44 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an ACR20 Response at Weeks 2, 4, 8, 12, 20, 28, 36, 44 and 52
Percentage of participantsPF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 221.67 (11.24 to 32.09)18.33 (8.54 to 28.12)18.75 (0.00 to 37.87)3.13 (0.00 to 11.65)5.88 (0.00 to 13.79)18.18 (5.02 to 31.34)
Week 445.00 (32.41 to 57.59)51.67 (39.02 to 64.31)31.25 (8.54 to 53.96)20.00 (0.00 to 40.24)14.71 (2.80 to 26.61)24.24 (9.62 to 38.86)
Week 866.67 (54.74 to 78.59)55.00 (42.41 to 67.59)50.00 (25.50 to 74.50)40.00 (15.21 to 64.79)35.29 (19.23 to 51.36)42.42 (25.56 to 59.29)
Week 1270.00 (58.40 to 81.60)63.33 (51.14 to 75.53)56.25 (31.94 to 80.56)60.00 (35.21 to 84.79)44.12 (27.43 to 60.81)39.39 (22.72 to 56.07)
Week 2081.67 (71.88 to 91.46)80.00 (69.88 to 90.12)68.75 (46.04 to 91.46)60.00 (35.21 to 84.79)73.53 (58.70 to 88.36)75.76 (61.14 to 90.38)
Week 2873.33 (62.14 to 84.52)78.33 (67.91 to 88.76)68.75 (46.04 to 91.46)73.33 (50.95 to 95.71)64.71 (48.64 to 80.77)81.82 (68.66 to 94.98)
Week 3666.67 (54.74 to 78.59)78.33 (67.91 to 88.76)68.75 (46.04 to 91.46)80.00 (59.76 to 100.00)64.71 (48.64 to 80.77)81.82 (68.66 to 94.98)
Week 4468.33 (56.56 to 80.10)73.33 (62.14 to 84.52)62.50 (38.78 to 86.22)73.33 (50.95 to 95.71)67.65 (51.92 to 83.37)75.76 (61.14 to 90.38)
Week 5261.67 (49.36 to 73.97)70.00 (58.40 to 81.60)56.25 (31.94 to 80.56)60.00 (35.21 to 84.79)61.76 (45.43 to 78.10)66.67 (50.58 to 82.75)
SecondaryPercentage of Participants Achieving an ACR50 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

The American College of Rheumatology's definition for calculating improvement in rheumatoid arthritis (ACR50) was calculated as a ≥50% improvement in tender and swollen joint counts and ≥50% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level).

Time frame:
Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an ACR50 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Percentage of participantsPF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 26.67 (0.35 to 12.98)1.67 (0.00 to 4.91)2.94 (0.00 to 10.97)3.13 (0.00 to 11.65)1.43 (0.00 to 5.36)1.47 (0.00 to 5.52)
Week 413.33 (4.73 to 21.93)16.67 (7.24 to 26.10)2.94 (0.00 to 10.97)6.67 (0.00 to 19.29)2.94 (0.00 to 8.62)6.06 (0.00 to 14.20)
Week 831.67 (19.90 to 43.44)25.00 (14.04 to 35.96)18.75 (0.00 to 37.87)13.33 (0.00 to 30.54)11.76 (0.93 to 22.59)15.15 (2.92 to 27.38)
Week 1243.33 (30.79 to 55.87)31.67 (19.90 to 43.44)31.25 (8.54 to 53.96)20.00 (0.00 to 40.24)23.53 (9.27 to 37.79)12.12 (0.99 to 23.26)
Week 1644.07 (31.40 to 56.74)48.33 (35.69 to 60.98)31.25 (8.54 to 53.96)33.33 (9.48 to 57.19)14.71 (2.80 to 26.61)6.06 (0.00 to 14.20)
Week 2061.67 (49.36 to 73.97)53.33 (40.71 to 65.96)37.50 (13.78 to 61.22)40.00 (15.21 to 64.79)44.12 (27.43 to 60.81)45.45 (28.47 to 62.44)
Week 2856.67 (44.13 to 69.21)51.67 (39.02 to 64.31)43.75 (19.44 to 68.06)53.33 (28.09 to 78.58)41.18 (24.63 to 57.72)66.67 (50.58 to 82.75)
Week 3653.33 (40.71 to 65.96)56.67 (44.13 to 69.21)50.00 (25.50 to 74.50)66.67 (42.81 to 90.52)50.00 (33.19 to 66.81)57.58 (40.71 to 74.44)
Week 4456.67 (44.13 to 69.21)55.00 (42.41 to 67.59)43.75 (19.44 to 68.06)60.00 (35.21 to 84.79)58.82 (42.28 to 75.37)63.64 (47.22 to 80.05)
Week 5246.67 (34.04 to 59.29)58.33 (45.86 to 70.81)43.75 (19.44 to 68.06)46.67 (21.42 to 71.91)41.18 (24.63 to 57.72)51.52 (34.46 to 68.57)
SecondaryPercentage of Participants Achieving an ACR70 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

The American College of Rheumatology's definition for calculating improvement in rheumatoid arthritis (ACR70) was calculated as a ≥70% improvement in tender and swollen joint counts and ≥70% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level).

Time frame:
Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an ACR70 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Percentage of participantsPF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 23.33 (0.00 to 7.88)1.67 (0.00 to 4.91)2.94 (0.00 to 10.97)3.13 (0.00 to 11.65)1.43 (0.00 to 5.36)1.47 (0.00 to 5.52)
Week 45.00 (0.00 to 10.51)5.00 (0.00 to 10.51)2.94 (0.00 to 10.97)3.13 (0.00 to 11.65)1.43 (0.00 to 5.36)1.47 (0.00 to 5.52)
Week 811.67 (3.54 to 19.79)11.67 (3.54 to 19.79)6.25 (0.00 to 18.11)3.13 (0.00 to 11.65)2.94 (0.00 to 8.62)3.03 (0.00 to 8.88)
Week 1221.67 (11.24 to 32.09)18.33 (8.54 to 28.12)6.25 (0.00 to 18.11)6.67 (0.00 to 19.29)1.43 (0.00 to 5.36)9.09 (0.00 to 18.90)
Week 1623.73 (12.87 to 34.58)26.67 (15.48 to 37.86)6.25 (0.00 to 18.11)13.33 (0.00 to 30.54)1.43 (0.00 to 5.36)1.47 (0.00 to 5.52)
Week 2035.00 (22.93 to 47.07)30.00 (18.40 to 41.60)12.50 (0.00 to 28.70)20.00 (0.00 to 40.24)23.53 (9.27 to 37.79)27.27 (12.08 to 42.47)
Week 2836.67 (24.47 to 48.86)38.33 (26.03 to 50.64)18.75 (0.00 to 37.87)26.67 (4.29 to 49.05)23.53 (9.27 to 37.79)42.42 (25.56 to 59.29)
Week 3640.00 (27.60 to 52.40)35.00 (22.93 to 47.07)37.50 (13.78 to 61.22)26.67 (4.29 to 49.05)35.29 (19.23 to 51.36)39.39 (22.72 to 56.07)
Week 4446.67 (34.04 to 59.29)45.00 (32.41 to 57.59)37.50 (13.78 to 61.22)40.00 (15.21 to 64.79)23.53 (9.27 to 37.79)51.52 (34.46 to 68.57)
Week 5238.33 (26.03 to 50.64)45.00 (32.41 to 57.59)31.25 (8.54 to 53.96)26.67 (4.29 to 49.05)35.29 (19.23 to 51.36)42.42 (25.56 to 59.29)
SecondaryChange From Baseline in Tender/Painful Joint Count at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

The tender/painful joints were assessed by a blinded assessor to determine the number of joints that were considered tender/painful using the following scale: Present/Absent/Not Done/Not Applicable (used for artificial or missing joints). Artificial joints was not assessed. Injected joints was counted according to their pre-injection status for the remainder of the study. The assessment was based on 68 joints. The score range was 0 to 68, with a higher score indicating a greater degree of tenderness. A negative change from baseline represents improvement.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in Tender/Painful Joint Count at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Units on a scalePF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 2-3.33 ± 5.23-2.7 ± 4.49-4.7 ± 6.370.0 ± 2.70-1.9 ± 3.27-2.1 ± 5.41
Week 4-6.3 ± 7.96-5.1 ± 5.43-5.6 ± 8.93-2.8 ± 4.49-3.4 ± 5.47-4.3 ± 8.25
Week 8-9.4 ± 7.69-6.8 ± 6.49-7.9 ± 7.89-4.4 ± 6.42-5.0 ± 6.46-4.6 ± 8.41
Week 12-9.8 ± 8.19-8.7 ± 7.27-11.3 ± 7.32-6.2 ± 8.43-6.5 ± 6.69-6.4 ± 9.40
Week 16-11.1 ± 8.01-10.1 ± 7.33-12.0 ± 8.80-10.4 ± 8.69-6.5 ± 5.78-6.5 ± 7.81
Week 20-12.2 ± 8.20-10.2 ± 6.60-13.6 ± 9.65-11.2 ± 10.95-8.8 ± 5.94-10.2 ± 7.41
Week 28-12.6 ± 8.38-10.4 ± 7.04-14.9 ± 9.99-13.5 ± 12.21-9.6 ± 6.39-11.4 ± 8.13
Week 36-12.5 ± 8.66-10.7 ± 7.00-16.2 ± 9.45-13.8 ± 11.89-10.4 ± 6.12-11.4 ± 8.82
Week 44-13.6 ± 8.54-11.6 ± 7.91-17.9 ± 10.07-12.6 ± 13.23-11.3 ± 6.47-12.5 ± 9.15
Week 52-13.6 ± 9.11-11.9 ± 7.69-18.9 ± 10.74-13.0 ± 12.25-10.8 ± 5.53-12.2 ± 9.81
SecondaryChange From Baseline in Swollen Joint Count at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

The swollen joints were assessed by a blinded assessor to determine the number of joints that were considered swollen using the following scale: Present/Absent/Not Done/Not Applicable (used for artificial or missing joints). Artificial joints was not assessed. Injected joints was counted according to their pre-injection status for the remainder of the study. The assessment was based on 66 joints. The score range was 0 to 66, with a higher score indicating a greater degree of swelling. A negative change from baseline represents improvement.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in Swollen Joint Count at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Units on a scalePF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 2-2.3 ± 3.48-2.7 ± 3.73-4.6 ± 5.46-2.1 ± 3.31-2.0 ± 3.82-2.0 ± 3.95
Week 4-4.8 ± 4.42-4.3 ± 3.64-5.5 ± 5.51-5.2 ± 8.14-2.5 ± 3.11-3.6 ± 5.61
Week 8-6.5 ± 5.42-5.9 ± 4.50-7.9 ± 4.72-7.5 ± 7.54-4.4 ± 5.42-4.4 ± 5.95
Week 12-7.1 ± 5.89-6.7 ± 4.69-8.7 ± 6.97-8.7 ± 8.04-5.4 ± 5.26-4.7 ± 6.05
Week 16-8.0 ± 5.53-7.6 ± 5.10-8.9 ± 7.94-9.9 ± 8.98-6.7 ± 5.80-5.5 ± 6.74
Week 20-8.5 ± 5.31-8.3 ± 5.12-10.5 ± 8.42-10.8 ± 9.10-8.0 ± 6.29-7.6 ± 5.15
Week 28-8.2 ± 4.34-7.7 ± 5.27-10.0 ± 7.66-10.9 ± 9.00-7.2 ± 5.79-8.5 ± 5.83
Week 36-8.1 ± 4.35-8.1 ± 4.97-10.5 ± 7.55-11.1 ± 9.30-8.4 ± 5.60-8.9 ± 5.71
Week 44-8.3 ± 4.87-8.2 ± 5.05-10.5 ± 6.84-10.8 ± 9.93-8.3 ± 5.57-9.5 ± 5.51
Week 52-8.2 ± 4.84-8.1 ± 4.84-11.1 ± 7.68-10.7 ± 9.55-8.5 ± 5.76-9.2 ± 6.19
SecondaryChange From Baseline in Patient's Assessment of Arthritis Pain at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

Participants assessed the severity of their arthritis pain using a 100 millimeter (mm) visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain. VAS data was rescaled prior to any calculation and analysis. Rescaled VAS score (mm) = (100 mm) × (length at mark in mm/overall length of line in mm). The score range was 0 mm to 100 mm, with a higher score indicating a higher degree of pain. A negative change from baseline represents improvement.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Mean · mm
Change From Baseline in Patient's Assessment of Arthritis Pain at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
mmPF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 2-7.6 ± 19.13-8.0 ± 17.96-5.3 ± 12.871.7 ± 21.20-2.3 ± 11.89-9.0 ± 17.52
Week 4-13.4 ± 23.39-18.5 ± 20.32-12.4 ± 22.60-7.9 ± 22.69-10.1 ± 18.67-9.6 ± 18.15
Week 8-20.6 ± 23.55-21.0 ± 22.46-14.3 ± 27.34-10.7 ± 25.94-16.9 ± 22.67-13.1 ± 22.88
Week 12-24.7 ± 25.72-22.8 ± 22.19-21.8 ± 24.25-14.9 ± 24.90-14.2 ± 24.54-12.3 ± 24.44
Week 16-28.4 ± 24.13-25.0 ± 22.58-26.5 ± 23.41-30.2 ± 20.55-13.7 ± 22.14-14.6 ± 20.16
Week 20-29.5 ± 24.12-30.9 ± 22.91-29.3 ± 24.07-25.5 ± 29.91-32.1 ± 22.84-27.7 ± 26.78
Week 28-29.7 ± 22.88-32.2 ± 25.21-34.6 ± 21.85-35.2 ± 24.79-29.6 ± 27.49-37.4 ± 25.54
Week 36-31.6 ± 25.14-31.3 ± 26.58-37.0 ± 29.87-33.5 ± 36.99-32.4 ± 21.11-38.5 ± 26.34
Week 44-32.8 ± 26.90-36.5 ± 26.87-41.6 ± 16.12-34.1 ± 39.69-35.0 ± 23.36-40.0 ± 26.21
Week 52-31.4 ± 26.39-35.5 ± 27.76-39.6 ± 21.95-34.9 ± 31.79-38.3 ± 22.84-38.5 ± 25.29
SecondaryChange From Baseline in Patient's Global Assessment of Arthritis at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?". The participant's response was recorded using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (very well) and 100 (very poorly). VAS data was rescaled prior to any calculation and analysis. Rescaled VAS score (mm) = (100 mm) × (length at mark in mm/overall length of line in mm). The score range was 0 mm to 100 mm, and a negative change from baseline represents improvement.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Mean · mm
Change From Baseline in Patient's Global Assessment of Arthritis at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
mmPF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 2-6.3 ± 21.52-10.9 ± 17.85-5.4 ± 17.592.6 ± 19.66-0.1 ± 17.33-7.8 ± 17.02
Week 4-14.4 ± 25.55-20.5 ± 20.60-12.3 ± 18.09-8.9 ± 16.46-2.0 ± 20.76-3.3 ± 17.34
Week 8-19.4 ± 24.61-21.9 ± 24.29-14.0 ± 21.37-12.7 ± 19.88-11.0 ± 26.22-7.0 ± 22.38
Week 12-21.8 ± 26.15-26.2 ± 21.18-20.0 ± 24.36-12.4 ± 21.29-12.2 ± 26.00-8.0 ± 25.46
Week 16-27.8 ± 22.31-27.3 ± 21.62-26.1 ± 25.26-26.7 ± 19.05-9.3 ± 23.48-9.4 ± 21.11
Week 20-26.8 ± 23.84-31.4 ± 21.81-27.6 ± 23.49-22.8 ± 31.26-28.8 ± 25.44-25.5 ± 24.96
Week 28-29.4 ± 20.78-34.0 ± 23.87-33.9 ± 22.09-33.7 ± 23.46-31.7 ± 24.10-33.9 ± 23.79
Week 36-30.1 ± 23.65-34.1 ± 26.03-37.2 ± 29.10-30.7 ± 39.29-28.5 ± 21.25-34.9 ± 24.80
Week 44-31.5 ± 24.77-34.9 ± 24.41-38.2 ± 22.88-33.0 ± 39.17-28.7 ± 23.22-35.6 ± 26.55
Week 52-32.0 ± 24.63-35.2 ± 28.60-36.8 ± 23.09-29.6 ± 32.56-34.9 ± 25.24-32.1 ± 28.85
SecondaryChange From Baseline in Physician's Global Assessment of Arthritis at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

The blinded assessor assessed the participant's overall arthritis appears at the time of each visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (very good) and 100 (very poor). VAS data was rescaled prior to any calculation and analysis. Rescaled VAS score (mm) = (100 mm) × (length at mark in mm/overall length of line in mm). The score range was 0 mm to 100 mm, and a negative change from baseline represents improvement.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Mean · mm
Change From Baseline in Physician's Global Assessment of Arthritis at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
mmPF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 2-9.2 ± 15.59-9.0 ± 14.87-9.9 ± 14.55-1.9 ± 10.79-3.4 ± 11.92-7.2 ± 13.64
Week 4-19.8 ± 18.98-17.6 ± 18.37-18.3 ± 22.31-11.1 ± 13.99-8.8 ± 17.67-9.5 ± 18.08
Week 8-30.6 ± 19.43-25.0 ± 18.02-28.7 ± 15.73-16.4 ± 21.08-16.3 ± 20.97-11.9 ± 17.94
Week 12-35.2 ± 19.92-30.1 ± 16.85-31.1 ± 20.62-21.2 ± 22.01-16.5 ± 21.57-13.7 ± 22.30
Week 16-37.7 ± 20.59-33.7 ± 17.89-31.2 ± 20.00-32.5 ± 23.98-16.5 ± 23.34-14.4 ± 27.76
Week 20-41.8 ± 19.91-37.8 ± 19.48-38.7 ± 24.67-34.7 ± 26.16-31.0 ± 22.29-27.1 ± 25.41
Week 28-42.0 ± 21.42-36.7 ± 21.91-47.6 ± 21.44-42.4 ± 23.28-32.7 ± 22.03-38.8 ± 20.53
Week 36-42.7 ± 22.92-36.8 ± 23.05-46.3 ± 22.42-43.4 ± 20.30-38.0 ± 19.52-42.6 ± 20.41
Week 44-44.5 ± 20.15-40.6 ± 22.19-51.9 ± 15.81-43.2 ± 25.55-36.4 ± 20.54-44.9 ± 20.40
Week 52-46.6 ± 21.73-43.4 ± 20.36-54.1 ± 15.18-42.7 ± 23.34-36.3 ± 21.01-41.9 ± 22.66
SecondaryChange From Baseline in Health Assessment Questionnaire (HAQ) Disability Index (DI) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

The HAQ-DI assessed the degree of difficulty a participant experienced in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question in the questionnaire, the level of difficulty is scored from 0 to 3 with 0 representing "no difficulty," 1 as "some difficulty," 2 as "much difficulty," and 3 as "unable to do". Any activity that requires assistance from another individual or requires the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range was 0 to 3, with a higher score indicating more difficulty in performing daily living activities. A negative change from baseline represents improvement.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in Health Assessment Questionnaire (HAQ) Disability Index (DI) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Units on a scalePF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 2-0.133 ± 0.4273-0.177 ± 0.3489-0.195 ± 0.2886-0.117 ± 0.4212-0.030 ± 0.4572-0.170 ± 0.3091
Week 4-0.248 ± 0.5341-0.315 ± 0.3777-0.180 ± 0.2090-0.217 ± 0.3356-0.095 ± 0.4931-0.170 ± 0.3305
Week 8-0.343 ± 0.5690-0.421 ± 0.4103-0.188 ± 0.4472-0.277 ± 0.3609-0.184 ± 0.4959-0.249 ± 0.4465
Week 12-0.366 ± 0.5701-0.478 ± 0.4167-0.214 ± 0.4230-0.304 ± 0.2930-0.121 ± 0.4910-0.239 ± 0.4660
Week 16-0.474 ± 0.5158-0.509 ± 0.3994-0.321 ± 0.3914-0.375 ± 0.3385-0.109 ± 0.5271-0.246 ± 0.3729
Week 20-0.466 ± 0.5546-0.576 ± 0.4906-0.404 ± 0.4681-0.308 ± 0.4610-0.363 ± 0.4983-0.472 ± 0.4934
Week 28-0.524 ± 0.5412-0.583 ± 0.5262-0.519 ± 0.4531-0.490 ± 0.5064-0.422 ± 0.4811-0.517 ± 0.5520
Week 36-0.520 ± 0.6051-0.594 ± 0.4990-0.577 ± 0.5740-0.519 ± 0.5633-0.329 ± 0.3816-0.547 ± 0.5867
Week 44-0.521 ± 0.6197-0.581 ± 0.5321-0.563 ± 0.3830-0.510 ± 0.5576-0.370 ± 0.4210-0.576 ± 0.5757
Week 52-0.503 ± 0.6023-0.567 ± 0.4866-0.500 ± 0.5137-0.552 ± 0.5041-0.411 ± 0.3695-0.514 ± 0.5704
SecondaryChange From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

C-reactive protein (hsCRP) is an acute phase reactant, which is indicative of inflammation and of its severity. Blood samples were obtained at Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52 for determination of hsCRP.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Mean · milligram per liter (mg/L)
Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
milligram per liter (mg/L)PF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 2-4.420 ± 8.9409-3.696 ± 11.9628-6.023 ± 19.1126-0.595 ± 1.4661-1.641 ± 10.42241.462 ± 7.8966
Week 4-3.645 ± 11.8144-5.543 ± 11.9617-6.134 ± 19.5633-1.324 ± 1.97350.010 ± 7.02061.206 ± 5.4423
Week 8-3.828 ± 10.8093-5.102 ± 11.5408-6.029 ± 19.9534-0.573 ± 2.6595-2.598 ± 10.72700.927 ± 6.2062
Week 12-3.759 ± 11.0481-5.881 ± 12.9484-7.335 ± 22.0149-1.177 ± 3.4854-1.061 ± 11.19441.021 ± 6.6025
Week 16-3.695 ± 8.1064-5.809 ± 13.6463-5.420 ± 21.96221.060 ± 8.7842-2.218 ± 11.6164-0.762 ± 6.5779
Week 20-4.581 ± 10.5026-6.014 ± 14.7723-7.879 ± 24.2763-0.989 ± 3.6969-5.982 ± 10.4711-4.718 ± 7.1896
Week 28-4.277 ± 12.9069-6.362 ± 13.6372-8.679 ± 24.9759-1.300 ± 3.7971-6.112 ± 10.6756-5.484 ± 10.0475
Week 36-4.899 ± 10.3015-5.940 ± 14.4219-9.461 ± 25.7767-1.814 ± 3.0658-6.247 ± 9.8145-5.029 ± 9.1947
Week 44-5.543 ± 11.7058-6.215 ± 14.2493-2.196 ± 2.2859-0.987 ± 3.7325-4.690 ± 9.9495-0.711 ± 13.7530
Week 52-5.167 ± 13.3963-4.880 ± 14.1148-1.586 ± 3.0576-2.028 ± 3.2177-4.324 ± 7.7335-4.722 ± 9.3318
SecondaryPercentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI 75) Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. Assessments of lesion Severity Score and Area Score are performed separately for each of the four body regions: head (including neck), upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). In each body region, the sum of the lesion Severity Scores for erythema, induration and scaling is multiplied by the Area Score which represents the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 indicates a 75% or greater reduction in PASI scores from baseline.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI 75) Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Percentage of participantsPF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 25.00 (0.00 to 11.75)2.56 (0.00 to 7.52)3.85 (0.00 to 14.30)11.11 (0.00 to 31.64)2.17 (0.00 to 8.13)5.26 (0.00 to 15.30)
Week 430.00 (15.80 to 44.20)12.82 (2.33 to 23.31)3.85 (0.00 to 14.30)11.11 (0.00 to 31.64)4.55 (0.00 to 13.25)5.26 (0.00 to 15.30)
Week 845.00 (29.58 to 60.42)41.03 (25.59 to 56.46)25.00 (0.50 to 49.50)11.11 (0.00 to 31.64)9.09 (0.00 to 21.10)15.79 (0.00 to 32.19)
Week 1260.00 (44.82 to 75.18)48.72 (33.03 to 64.41)33.33 (6.66 to 60.01)33.33 (2.54 to 64.13)18.18 (2.06 to 34.30)21.05 (2.72 to 39.38)
Week 1669.23 (54.75 to 83.72)58.97 (43.54 to 74.41)58.33 (30.44 to 86.23)55.56 (23.09 to 88.02)22.73 (5.22 to 40.24)26.32 (6.52 to 46.12)
Week 2072.50 (58.66 to 86.34)61.54 (46.27 to 76.81)66.67 (39.99 to 93.34)55.56 (23.09 to 88.02)54.55 (33.74 to 75.35)36.84 (15.15 to 58.53)
Week 2870.00 (55.80 to 84.20)51.28 (35.59 to 66.97)91.67 (76.03 to 100.00)77.78 (50.62 to 100.00)63.64 (43.54 to 83.74)63.16 (41.47 to 84.85)
Week 3670.00 (55.80 to 84.20)64.10 (49.05 to 79.16)96.15 (85.70 to 100.00)88.89 (68.36 to 100.00)59.09 (38.55 to 79.64)47.37 (24.92 to 69.82)
Week 4475.00 (61.58 to 88.42)66.67 (51.87 to 81.46)75.00 (50.50 to 99.50)55.56 (23.09 to 88.02)63.64 (43.54 to 83.74)63.16 (41.47 to 84.85)
Week 5265.00 (50.22 to 79.78)66.67 (51.87 to 81.46)66.67 (39.99 to 93.34)66.67 (35.87 to 97.46)50.00 (29.11 to 70.89)57.89 (35.69 to 80.10)
SecondaryPercentage of Participants Achieving a PASI 90 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. Assessments of lesion Severity Score and Area Score are performed separately for each of the four body regions: head (including neck), upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). In each body region, the sum of the lesion Severity Scores for erythema, induration and scaling is multiplied by the Area Score which represents the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 indicates a 90% or greater reduction in PASI scores from baseline.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a PASI 90 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Percentage of participantsPF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 21.22 (0.00 to 4.58)1.25 (0.00 to 4.69)3.85 (0.00 to 14.30)11.11 (0.00 to 31.64)2.17 (0.00 to 8.13)2.50 (0.00 to 9.34)
Week 417.50 (5.72 to 29.28)5.13 (0.00 to 12.05)3.85 (0.00 to 14.30)11.11 (0.00 to 31.64)4.55 (0.00 to 13.25)2.50 (0.00 to 9.34)
Week 835.00 (20.22 to 49.78)17.95 (5.90 to 29.99)16.67 (0.00 to 37.75)11.11 (0.00 to 31.64)2.17 (0.00 to 8.13)5.26 (0.00 to 15.30)
Week 1247.50 (32.02 to 62.98)25.64 (11.94 to 39.35)16.67 (0.00 to 37.75)22.22 (0.00 to 49.38)2.17 (0.00 to 8.13)10.53 (0.00 to 24.33)
Week 1653.85 (38.20 to 69.49)33.33 (18.54 to 48.13)33.33 (6.66 to 60.01)33.33 (2.54 to 64.13)9.09 (0.00 to 21.10)15.79 (0.00 to 32.19)
Week 2050.00 (34.51 to 65.49)43.59 (28.03 to 59.15)50.00 (21.71 to 78.29)44.44 (11.98 to 76.91)18.18 (2.06 to 34.30)26.32 (6.52 to 46.12)
Week 2852.50 (37.02 to 67.98)38.46 (23.19 to 53.73)58.33 (30.44 to 86.23)44.44 (11.98 to 76.91)50.00 (29.11 to 70.89)31.58 (10.68 to 52.48)
Week 3662.50 (47.50 to 77.50)48.72 (33.03 to 64.41)83.33 (62.25 to 100.00)66.67 (35.87 to 97.46)45.45 (24.65 to 66.26)36.84 (15.15 to 58.53)
Week 4452.50 (37.02 to 67.98)48.72 (33.03 to 64.41)66.67 (39.99 to 93.34)44.44 (11.98 to 76.91)50.00 (29.11 to 70.89)52.63 (30.18 to 75.08)
Week 5240.00 (24.82 to 55.18)56.41 (40.85 to 71.97)66.67 (39.99 to 93.34)55.56 (23.09 to 88.02)45.45 (24.65 to 66.26)47.37 (24.92 to 69.82)
SecondaryPercentage of Participants Achieving a PASI 100 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. Assessments of lesion Severity Score and Area Score are performed separately for each of the four body regions: head (including neck), upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). In each body region, the sum of the lesion Severity Scores for erythema, induration and scaling is multiplied by the Area Score which represents the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 100 indicates a 100% reduction in PASI scores from baseline.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a PASI 100 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Percentage of participantsPF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 21.22 (0.00 to 4.58)1.25 (0.00 to 4.69)3.85 (0.00 to 14.30)11.11 (0.00 to 31.64)2.17 (0.00 to 8.13)2.50 (0.00 to 9.34)
Week 47.50 (0.00 to 15.66)1.25 (0.00 to 4.69)3.85 (0.00 to 14.30)5.00 (0.00 to 18.51)4.55 (0.00 to 13.25)2.50 (0.00 to 9.34)
Week 820.00 (7.60 to 32.40)5.13 (0.00 to 12.05)8.33 (0.00 to 23.97)11.11 (0.00 to 31.64)2.17 (0.00 to 8.13)2.50 (0.00 to 9.34)
Week 1235.00 (20.22 to 49.78)7.69 (0.00 to 16.06)8.33 (0.00 to 23.97)11.11 (0.00 to 31.64)2.17 (0.00 to 8.13)5.26 (0.00 to 15.30)
Week 1635.90 (20.84 to 50.95)15.38 (4.06 to 26.71)16.67 (0.00 to 37.75)33.33 (2.54 to 64.13)9.09 (0.00 to 21.10)10.53 (0.00 to 24.33)
Week 2027.50 (13.66 to 41.34)35.90 (20.84 to 50.95)33.33 (6.66 to 60.01)44.44 (11.98 to 76.91)13.64 (0.00 to 27.98)10.53 (0.00 to 24.33)
Week 2835.00 (20.22 to 49.78)30.77 (16.28 to 45.25)50.00 (21.71 to 78.29)44.44 (11.98 to 76.91)40.91 (20.36 to 61.45)21.05 (2.72 to 39.38)
Week 3640.00 (24.82 to 55.18)35.90 (20.84 to 50.95)50.00 (21.71 to 78.29)55.56 (23.09 to 88.02)36.36 (16.26 to 56.46)21.05 (2.72 to 39.38)
Week 4430.00 (15.80 to 44.20)41.03 (25.59 to 56.46)58.33 (30.44 to 86.23)44.44 (11.98 to 76.91)31.82 (12.36 to 51.28)42.11 (19.90 to 64.31)
Week 5235.00 (20.22 to 49.78)38.46 (23.19 to 53.73)41.67 (13.77 to 69.56)33.33 (2.54 to 64.13)36.36 (16.26 to 56.46)42.11 (19.90 to 64.31)
SecondaryChange From Baseline in the Enthesitis Score (Using the Spondyloarthritis Research Consortium of Canada [SPARCC] Enthesitis Index) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

The SPARCC Enthesitis Index examines tenderness at sixteen sites: medial epicondyle humerus, lateral epicondyle humerus, supraspinatus insertion into greater tuberosity of humerus, greater trochanter, quadriceps insertion into superior border of patella, patellar ligament insertion into inferior pole of patella or tibial tubercle (considered 1 site for scoring purposes), Achilles tendon insertion into calcaneum and plantar fascia insertion into calcaneum. Each site is classified on a dichotomous basis as either tender (score=1) or not tender (score=0). The SPARCC Enthesitis Index scores range from 0-16, with higher scores indicating higher disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in the Enthesitis Score (Using the Spondyloarthritis Research Consortium of Canada [SPARCC] Enthesitis Index) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Units on a scalePF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 2-0.6 ± 1.55-0.3 ± 2.73-1.4 ± 1.860.0 ± 1.12-0.2 ± 1.79-0.3 ± 2.67
Week 4-1.4 ± 2.41-0.9 ± 2.32-1.3 ± 2.370.0 ± 1.41-1.0 ± 2.29-1.0 ± 2.81
Week 8-1.9 ± 2.11-1.9 ± 2.23-1.4 ± 1.80-1.0 ± 1.07-1.1 ± 2.50-1.2 ± 2.53
Week 12-2.1 ± 2.49-1.6 ± 2.22-2.7 ± 1.73-1.3 ± 1.04-1.7 ± 2.52-1.1 ± 3.00
Week 16-2.1 ± 2.68-1.3 ± 1.89-3.1 ± 1.27-0.3 ± 2.71-1.8 ± 2.94-1.2 ± 2.79
Week 20-2.3 ± 2.66-1.9 ± 2.29-3.2 ± 3.03-1.3 ± 0.89-2.1 ± 2.24-1.9 ± 2.71
Week 28-2.4 ± 2.68-2.3 ± 2.60-3.8 ± 2.05-1.4 ± 1.19-2.5 ± 2.97-3.1 ± 2.60
Week 36-2.6 ± 2.70-2.3 ± 2.28-3.8 ± 2.79-1.6 ± 1.06-2.1 ± 2.51-2.8 ± 2.60
Week 44-2.9 ± 2.56-2.4 ± 2.53-3.3 ± 1.67-1.6 ± 1.06-2.1 ± 2.57-3.2 ± 2.44
Week 52-3.1 ± 2.55-2.4 ± 2.34-4.8 ± 2.76-1.5 ± 0.76-2.2 ± 1.74-3.6 ± 2.59
SecondaryChange From Baseline in the Enthesitis Score (Using the Leeds Enthesitis Index) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

The Leeds Enthesitis Index (LEI) examines tenderness at six sites: lateral epicondyle humerus, medial femoral condyle and Achilles tendon insertion. Each site is assessed as either tender (score=1) or not tender (score=0). The LEI scores range from 0-6, with higher scores indicating higher disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in the Enthesitis Score (Using the Leeds Enthesitis Index) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Units on a scalePF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 2-0.4 ± 0.95-0.4 ± 1.53-0.5 ± 1.270.0 ± 0.53-0.1 ± 1.12-0.3 ± 0.82
Week 4-0.7 ± 1.56-0.9 ± 1.48-1.0 ± 1.25-0.1 ± 0.99-0.4 ± 0.75-0.9 ± 1.62
Week 8-1.3 ± 1.43-1.2 ± 1.47-0.5 ± 1.78-0.4 ± 0.98-0.5 ± 1.31-0.7 ± 1.49
Week 12-1.2 ± 1.93-1.5 ± 1.42-1.0 ± 1.22-1.1 ± 0.90-0.9 ± 0.94-0.9 ± 1.79
Week 16-1.4 ± 1.63-1.5 ± 1.45-1.2 ± 0.83-0.1 ± 2.12-0.9 ± 1.13-0.9 ± 1.54
Week 20-1.6 ± 1.52-1.3 ± 1.80-1.7 ± 2.65-0.9 ± 0.90-1.1 ± 0.90-1.4 ± 1.91
Week 28-1.4 ± 1.56-1.7 ± 1.57-1.9 ± 2.20-1.3 ± 0.76-1.1 ± 1.20-1.7 ± 1.54
Week 36-1.9 ± 1.36-1.8 ± 1.59-2.3 ± 1.50-1.1 ± 0.90-1.1 ± 1.17-1.7 ± 1.44
Week 44-1.8 ± 1.47-1.8 ± 1.65-2.3 ± 1.04-1.3 ± 0.76-1.2 ± 1.19-1.9 ± 1.41
Week 52-2.0 ± 1.54-1.7 ± 1.40-2.5 ± 0.93-1.0 ± 0.82-1.2 ± 0.73-1.8 ± 1.70
SecondaryChange From Baseline in the Dactylitis Severity Score (DSS) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

The number of digits in hands and feet with dactylitis was evaluated by a blinded assessor. In addition, dactylitis severity was scored based upon digit tenderness using a scale of 0-3, where 0 = no tenderness to 3 = extreme tenderness, in each digit of the hands and feet. The range of total dactylitis scores was 0-60, with higher scores indicating greater severity. A negative change from baseline represents improvement.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in the Dactylitis Severity Score (DSS) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Units on a scalePF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 2-0.2 ± 2.36-0.7 ± 2.54-2.7 ± 4.62-0.5 ± 1.38-0.7 ± 1.610.2 ± 2.28
Week 4-1.6 ± 3.30-2.2 ± 3.15-3.3 ± 3.21-0.8 ± 1.17-1.2 ± 2.59-0.3 ± 3.12
Week 8-3.5 ± 4.31-4.0 ± 3.22-4.3 ± 4.16-1.7 ± 1.37-2.5 ± 6.14-1.8 ± 2.82
Week 12-4.4 ± 3.34-4.5 ± 3.30-4.3 ± 4.93-3.2 ± 3.43-4.8 ± 7.07-2.8 ± 4.49
Week 16-3.7 ± 3.85-4.9 ± 4.06-4.7 ± 6.35-3.7 ± 4.13-5.4 ± 7.44-2.9 ± 6.01
Week 20-4.4 ± 3.31-4.6 ± 4.23-5.3 ± 5.86-3.7 ± 4.13-7.0 ± 7.44-4.4 ± 6.11
Week 28-3.8 ± 3.67-5.1 ± 4.08-5.3 ± 5.86-3.7 ± 4.13-6.6 ± 7.18-4.7 ± 7.05
Week 36-4.2 ± 4.02-5.1 ± 4.26-5.7 ± 5.69-3.7 ± 4.13-6.8 ± 7.34-5.3 ± 7.40
Week 44-5.0 ± 3.65-5.4 ± 4.01-5.7 ± 5.69-3.7 ± 4.13-6.8 ± 7.34-5.3 ± 7.40
Week 52-5.0 ± 3.65-5.4 ± 4.05-5.7 ± 5.69-3.7 ± 4.13-5.0 ± 5.40-5.7 ± 8.62
SecondaryChange From Baseline in the Nail Psoriasis Severity Index (NAPSI) Score at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

A target finger nail was evaluated by the blinded assessor using the NAPSI scale. At the baseline visit, the worst case fingernail was chosen and the same nail was evaluated consistently through the entire study. Each quadrant of the target nail was graded for nail matrix psoriasis (including any of the following parameters: pitting, leukonychia, red spots in lunula, nail plate crumbling) and nail bed psoriasis (including any of the following parameters: onycholysis, splinter hemorrhages, oil drop (salmon patch) discoloration, nail bed hyperkeratosis). The target nail NAPSI scores range from 0 to 8, with higher scores indicating higher disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in the Nail Psoriasis Severity Index (NAPSI) Score at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Units on a scalePF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 2-0.4 ± 1.550.1 ± 0.65-0.4 ± 0.520.3 ± 0.71-0.2 ± 1.040.1 ± 0.25
Week 4-1.0 ± 2.09-0.5 ± 1.70-0.9 ± 1.10-0.3 ± 0.46-1.0 ± 2.16-0.3 ± 0.95
Week 8-2.0 ± 2.40-1.0 ± 1.49-1.1 ± 1.52-1.1 ± 1.57-1.3 ± 2.55-0.6 ± 1.55
Week 12-2.8 ± 2.54-1.8 ± 2.43-0.5 ± 2.88-1.9 ± 2.97-1.2 ± 2.62-1.3 ± 1.82
Week 16-3.2 ± 2.71-1.7 ± 2.54-1.5 ± 2.00-2.9 ± 3.08-1.4 ± 2.61-1.6 ± 1.76
Week 20-3.7 ± 2.82-2.3 ± 2.31-2.1 ± 2.41-3.1 ± 2.97-2.0 ± 2.61-1.9 ± 1.81
Week 28-3.9 ± 2.90-2.4 ± 2.56-3.1 ± 2.12-3.3 ± 2.93-2.2 ± 2.59-2.5 ± 1.83
Week 36-3.9 ± 3.06-2.5 ± 2.51-3.3 ± 1.98-3.3 ± 3.15-2.8 ± 2.71-2.9 ± 1.75
Week 44-4.2 ± 2.77-2.8 ± 2.47-4.2 ± 2.05-3.8 ± 3.19-2.8 ± 2.61-2.6 ± 1.71
Week 52-4.2 ± 2.62-2.6 ± 2.80-3.6 ± 2.07-3.7 ± 3.27-3.1 ± 2.91-2.7 ± 1.30
SecondaryChange From Baseline in the Patient's Global Joint and Skin Assessment-Visual Analog Scale (PGJS-VAS) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

Participant's perception of disease was assessed using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (excellent) and 100 (poor). The rating corresponded to the way in which the participant felt over the past week in terms of how they were affected by their: 1) psoriasis and arthritis (global, PGA); 2) arthritis only (PJA) and 3) psoriasis only (PSA). Rescaled VAS score was used. Rescaled VAS score (mm) = (100 mm) × (length at mark in mm/overall length of line in mm). A negative change from baseline represents improvement.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Mean · mm
Change From Baseline in the Patient's Global Joint and Skin Assessment-Visual Analog Scale (PGJS-VAS) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
mmPF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 2-8.9 ± 26.88-11.6 ± 22.31-4.9 ± 12.42-0.5 ± 12.41-3.3 ± 14.50-7.1 ± 17.44
Week 4-17.0 ± 24.83-18.8 ± 25.42-13.2 ± 18.69-7.1 ± 21.61-11.6 ± 22.07-6.2 ± 24.53
Week 8-21.1 ± 26.95-19.7 ± 27.56-12.0 ± 26.52-16.4 ± 25.36-16.8 ± 26.21-8.1 ± 24.41
Week 12-25.1 ± 28.18-25.3 ± 23.75-18.0 ± 21.42-17.6 ± 23.70-14.4 ± 28.78-9.5 ± 23.74
Week 16-29.0 ± 24.78-24.5 ± 25.43-23.9 ± 21.10-27.8 ± 21.23-11.7 ± 23.36-9.9 ± 23.87
Week 20-29.1 ± 24.08-30.5 ± 23.29-27.3 ± 24.19-22.6 ± 27.92-36.3 ± 22.12-26.3 ± 29.72
Week 28-30.0 ± 24.53-29.7 ± 28.36-37.2 ± 22.80-38.8 ± 25.73-37.3 ± 25.35-37.2 ± 24.64
Week 36-29.1 ± 27.81-29.6 ± 27.90-42.0 ± 26.37-33.7 ± 27.04-36.0 ± 22.02-39.4 ± 26.35
Week 44-33.6 ± 28.52-32.4 ± 28.81-41.9 ± 19.08-36.8 ± 30.62-38.2 ± 26.65-42.1 ± 27.08
Week 52-33.3 ± 28.68-32.7 ± 29.77-35.6 ± 26.94-33.9 ± 33.45-39.1 ± 23.78-38.3 ± 30.58
SecondaryChange From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52

The FACIT-F Scale is a patient completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue).

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52
Units on a scalePF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 22.0 ± 5.823.1 ± 5.850.9 ± 2.601.2 ± 6.450.9 ± 6.952.7 ± 6.07
Week 42.4 ± 7.475.7 ± 7.343.7 ± 5.403.7 ± 8.303.0 ± 10.762.5 ± 6.98
Week 84.2 ± 8.035.6 ± 8.443.6 ± 5.783.8 ± 6.243.2 ± 10.313.7 ± 9.92
Week 124.7 ± 10.177.3 ± 7.963.2 ± 4.106.1 ± 7.855.5 ± 9.553.8 ± 9.85
Week 165.6 ± 7.747.1 ± 9.414.4 ± 5.406.0 ± 6.894.7 ± 8.104.7 ± 8.99
Week 206.6 ± 8.699.5 ± 8.207.2 ± 5.867.0 ± 7.948.9 ± 8.119.3 ± 9.20
Week 287.7 ± 9.679.5 ± 8.227.2 ± 7.7312.3 ± 11.489.8 ± 10.0211.7 ± 10.41
Week 367.4 ± 9.518.4 ± 8.257.3 ± 5.5410.6 ± 11.369.6 ± 6.4811.3 ± 11.23
Week 447.8 ± 9.0010.0 ± 9.527.9 ± 5.0713.1 ± 11.107.7 ± 7.8911.8 ± 11.35
Week 527.8 ± 8.5410.4 ± 9.869.4 ± 9.0112.3 ± 12.7410.5 ± 8.9110.5 ± 10.62
SecondaryChange From Baseline in the Short-Form-36 Health Survey (SF-36) Version 2, Acute at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52

The SF-36 version 2 (Acute version) is a 36-item generic health status measure. It measures 8 general health concepts or domains: Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH). These 8 domains can also be summarized as physical and mental component scores. The summary component scores, Physical Component Summary (PCS) and Mental Component Summary (MCS), are based on a normalized sum of the 8 scale scores PF, RP, BP, GH, VT, SF, RE, and MH. All domains and summary components are scored such that a higher score indicates a higher functioning or health level. The minimum and maximum scores of the PCS Score are 22 and 59 respectively. The minimum and maximum scores of the MCS Score are 11 and 62 respectively.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in the Short-Form-36 Health Survey (SF-36) Version 2, Acute at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52
Units on a scalePF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 4 (Physical Component Summary Score)3.29 ± 7.0924.24 ± 7.6022.59 ± 5.2631.01 ± 3.9441.66 ± 5.8452.64 ± 6.299
Week 8 (Physical Component Summary Score)4.21 ± 8.2975.97 ± 8.2615.53 ± 9.3872.47 ± 3.6752.57 ± 6.4573.04 ± 5.529
Week 12 (Physical Component Summary Score)4.09 ± 8.4034.86 ± 9.0107.28 ± 7.2322.29 ± 4.2832.22 ± 6.2053.07 ± 7.330
Week 16 (Physical Component Summary Score)5.40 ± 8.2397.27 ± 8.6276.97 ± 7.2235.07 ± 4.7632.36 ± 6.8421.79 ± 6.101
Week 20 (Physical Component Summary Score)4.75 ± 8.5798.84 ± 8.2319.53 ± 8.4342.03 ± 6.7566.14 ± 7.5136.25 ± 8.447
Week 28 (Physical Component Summary Score)6.16 ± 8.6919.06 ± 9.5979.42 ± 7.7517.84 ± 7.1275.67 ± 7.9339.22 ± 8.890
Week 36 (Physical Component Summary Score)6.58 ± 9.5107.75 ± 9.2239.08 ± 9.7896.44 ± 7.2455.96 ± 6.7389.41 ± 8.940
Week 44 (Physical Component Summary Score)6.67 ± 9.5419.23 ± 9.4778.44 ± 9.5277.13 ± 6.7596.00 ± 6.9379.18 ± 8.199
Week 52 (Physical Component Summary Score)6.52 ± 9.8189.98 ± 9.1509.55 ± 9.5366.64 ± 7.9257.21 ± 8.1309.84 ± 9.347
Week 4 (Mental Component Summary Score)-0.28 ± 10.6433.79 ± 9.1391.24 ± 5.4263.99 ± 10.7230.45 ± 7.539-1.09 ± 9.805
Week 8 (Mental Component Summary Score)0.84 ± 9.8102.84 ± 10.894-2.05 ± 10.5536.91 ± 10.4500.29 ± 10.2530.75 ± 8.880
Week 12 (Mental Component Summary Score)0.85 ± 9.8604.99 ± 10.3070.78 ± 8.4885.15 ± 13.1891.37 ± 11.2611.50 ± 9.640
Week 16 (Mental Component Summary Score)2.25 ± 10.8482.12 ± 11.3691.01 ± 6.9954.78 ± 10.9302.83 ± 8.4593.03 ± 9.824
Week 20 (Mental Component Summary Score)2.44 ± 10.1313.59 ± 10.7632.76 ± 8.5956.58 ± 10.7964.99 ± 8.7826.72 ± 8.781
Week 28 (Mental Component Summary Score)3.85 ± 11.2953.64 ± 11.0043.54 ± 7.2908.95 ± 12.9146.08 ± 7.7646.57 ± 9.590
Week 36 (Mental Component Summary Score)3.98 ± 9.0445.41 ± 11.6494.74 ± 9.3018.53 ± 14.2106.58 ± 7.4195.47 ± 10.182
Week 44 (Mental Component Summary Score)5.14 ± 9.7454.43 ± 13.6014.29 ± 10.6417.70 ± 13.6066.33 ± 7.7854.98 ± 10.544
Week 52 (Mental Component Summary Score)4.12 ± 10.0234.33 ± 13.3033.63 ± 10.6568.69 ± 16.1925.68 ± 8.7834.35 ± 10.770
SecondaryPercentage of Participants Achieving Minimal Disease Activity (MDA) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52

A psoriatic arthritis participant was defined as having MDA response when 5 of the 7 following criteria were met: 1) tender joint count ≤1; 2) swollen joint count ≤1; 3) Psoriasis Area and Severity Index (quantifying the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area affected) score ≤1 or Body Surface Area (assessment of body surface area involved in psoriasis) ≤3%; 4) Patient's Assessment of Arthritis Pain (assessment of the patient's level of pain using a horizontal 100 mm visual analog scale) ≤15 mm; 5) Patient's Global Arthritis Assessment (patient's overall assessment of how the arthritis was doing by a 100 mm visual analog scale) ≤20 mm; 6) Health Assessment Questionnaire - Disability Index (assessment of the degree of difficulty a patient experienced) score ≤0.5; 7) tender entheseal points (assessment of tenderness using Leed's Enthesitis Index) ≤1.

Time frame:
Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Minimal Disease Activity (MDA) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52
Percentage of participantsPF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 48.33 (1.34 to 15.33)8.33 (1.34 to 15.33)6.25 (0.00 to 18.11)3.13 (0.00 to 11.65)1.43 (0.00 to 5.36)3.03 (0.00 to 8.88)
Week 826.67 (15.48 to 37.86)21.67 (11.24 to 32.09)18.75 (0.00 to 37.87)6.67 (0.00 to 19.29)5.88 (0.00 to 13.79)12.12 (0.99 to 23.26)
Week 1231.67 (19.90 to 43.44)25.00 (14.04 to 35.96)18.75 (0.00 to 37.87)20.00 (0.00 to 40.24)5.88 (0.00 to 13.79)12.12 (0.99 to 23.26)
Week 1635.59 (23.38 to 47.81)35.00 (22.93 to 47.07)18.75 (0.00 to 37.87)20.00 (0.00 to 40.24)2.94 (0.00 to 8.62)3.03 (0.00 to 8.88)
Week 2045.00 (32.41 to 57.59)38.33 (26.03 to 50.64)25.00 (3.78 to 46.22)26.67 (4.29 to 49.05)29.41 (14.10 to 44.73)24.24 (9.62 to 38.86)
Week 2843.33 (30.79 to 55.87)46.67 (34.04 to 59.29)31.25 (8.54 to 53.96)33.33 (9.48 to 57.19)32.35 (16.63 to 48.08)45.45 (28.47 to 62.44)
Week 3643.33 (30.79 to 55.87)43.33 (30.79 to 55.87)50.00 (25.50 to 74.50)60.00 (35.21 to 84.79)29.41 (14.10 to 44.73)57.58 (40.71 to 74.44)
Week 4453.33 (40.71 to 65.96)50.00 (37.35 to 62.65)31.25 (8.54 to 53.96)46.67 (21.42 to 71.91)32.35 (16.63 to 48.08)51.52 (34.46 to 68.57)
Week 5246.67 (34.04 to 59.29)48.33 (35.69 to 60.98)31.25 (8.54 to 53.96)40.00 (15.21 to 64.79)41.18 (24.63 to 57.72)45.45 (28.47 to 62.44)
SecondaryPercentage of Participants Achieving Very Low Disease Activity (VLDA) Response at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52

A participant was in VLDA when all the 7 following criteria were met: 1) tender joint count ≤1; 2) swollen joint count ≤1; 3) Psoriasis Area and Severity Index (quantifying the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area affected) score ≤1 or Body Surface Area (assessment of body surface area involved in psoriasis) ≤3%; 4) Patient's Assessment of Arthritis Pain (assessment of the patient's level of pain using a horizontal 100 mm visual analog scale) ≤15 mm; 5) Patient's Global Arthritis Assessment (patient's overall assessment of how the arthritis was doing by a 100 mm visual analog scale) ≤20 mm; 6) Health Assessment Questionnaire - Disability Index (assessment of the degree of difficulty a patient experienced) score ≤0.5; 7) tender entheseal points (assessment of tenderness using Leed's Enthesitis Index) ≤1.

Time frame:
Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Very Low Disease Activity (VLDA) Response at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52
Percentage of participantsPF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 40.82 (0.00 to 3.08)0.82 (0.00 to 3.08)2.94 (0.00 to 10.97)3.13 (0.00 to 11.65)1.43 (0.00 to 5.36)1.47 (0.00 to 5.52)
Week 81.67 (0.00 to 4.91)1.67 (0.00 to 4.91)2.94 (0.00 to 10.97)3.13 (0.00 to 11.65)1.43 (0.00 to 5.36)1.47 (0.00 to 5.52)
Week 120.82 (0.00 to 3.08)3.33 (0.00 to 7.88)2.94 (0.00 to 10.97)3.13 (0.00 to 11.65)1.43 (0.00 to 5.36)1.47 (0.00 to 5.52)
Week 163.39 (0.00 to 8.01)5.00 (0.00 to 10.51)6.25 (0.00 to 18.11)3.13 (0.00 to 11.65)1.43 (0.00 to 5.36)1.47 (0.00 to 5.52)
Week 206.67 (0.35 to 12.98)11.67 (3.54 to 19.79)12.50 (0.00 to 28.70)13.33 (0.00 to 30.54)2.94 (0.00 to 8.62)1.47 (0.00 to 5.52)
Week 2810.00 (2.41 to 17.59)10.00 (2.41 to 17.59)12.50 (0.00 to 28.70)6.67 (0.00 to 19.29)8.82 (0.00 to 18.36)6.06 (0.00 to 14.20)
Week 3615.00 (5.97 to 24.03)15.00 (5.97 to 24.03)12.50 (0.00 to 28.70)6.67 (0.00 to 19.29)5.88 (0.00 to 13.79)12.12 (0.99 to 23.26)
Week 4415.00 (5.97 to 24.03)16.67 (7.24 to 26.10)18.75 (0.00 to 37.87)20.00 (0.00 to 40.24)14.71 (2.80 to 26.61)15.15 (2.92 to 27.38)
Week 5220.00 (9.88 to 30.12)16.67 (7.24 to 26.10)25.00 (3.78 to 46.22)20.00 (0.00 to 40.24)11.76 (0.93 to 22.59)18.18 (5.02 to 31.34)
SecondaryChange From Baseline in the Disease Activity Index for Reactive Arthritis/PsA (DAREA/DAPSA) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52

DAREA/DAPSA is a composite instrument to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender/painful joint count + swollen joint count (using SJC66/ TJC68 assessments), Patient's Global Assessment of Arthritis (PtGA in cm), Patient's Assessment of Arthritis Pain (PAIN in cm) and C-reactive protein (CRP) (in mg/dL). Since DAREA reflects domains found important in PsA, it has been proposed to serve as a Disease Activity Index for Psoriatic Arthritis (DAPSA). DAREA/DAPSA was calculated as follows: DAREA/DAPSA= SJC66 + TJC68 + PtGA + PAIN + CRP. A negative change from baseline represents improvement.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in the Disease Activity Index for Reactive Arthritis/PsA (DAREA/DAPSA) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52
Units on a scalePF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 4-14.05 ± 11.826-13.99 ± 10.166-14.15 ± 14.294-9.81 ± 13.841-7.11 ± 8.738-9.08 ± 12.074
Week 8-20.36 ± 11.211-17.55 ± 11.664-19.19 ± 11.720-14.33 ± 15.143-12.46 ± 12.905-10.98 ± 15.222
Week 12-21.93 ± 12.582-20.91 ± 11.985-24.91 ± 15.556-17.77 ± 18.471-14.68 ± 12.943-13.04 ± 15.072
Week 16-25.15 ± 12.582-23.55 ± 12.040-26.65 ± 16.982-25.89 ± 18.513-15.83 ± 12.918-14.45 ± 15.150
Week 20-26.75 ± 13.625-25.24 ± 12.152-30.63 ± 17.150-27.01 ± 22.334-23.53 ± 13.606-23.63 ± 13.640
Week 28-27.13 ± 12.807-25.38 ± 13.129-32.63 ± 18.437-31.41 ± 22.145-23.54 ± 12.375-27.55 ± 14.831
Week 36-27.21 ± 14.456-25.84 ± 13.170-34.98 ± 19.857-31.53 ± 24.046-25.57 ± 11.445-28.22 ± 15.793
Week 44-28.39 ± 14.445-27.54 ± 12.744-36.61 ± 14.597-30.22 ± 27.532-26.43 ± 10.880-29.59 ± 15.962
Week 52-28.56 ± 15.578-27.40 ± 13.429-37.81 ± 14.251-30.32 ± 22.795-26.45 ± 11.114-28.95 ± 17.706
SecondaryPercentage of Participants Achieving the Psoriatic Arthritis Response Criteria (PsARC) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52

The PsARC response was defined as improvement in two of the following 4 criteria, one of which must be joint pain or swelling, without worsening in any measure: (1) ≥20% improvement in Physician's Global Assessment of Arthritis (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity); (2) ≥20% improvement in Patient's Global Assessment of Arthritis (the patient's overall assessment of how the arthritis was doing by a visual analog scale); (3) ≥30% improvement in tender joint count (68); and (4) ≥30% improvement in swollen joint count.

Time frame:
Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving the Psoriatic Arthritis Response Criteria (PsARC) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52
Percentage of participantsPF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 450.00 (37.35 to 62.65)55.00 (42.41 to 67.59)50.00 (25.50 to 74.50)40.00 (15.21 to 64.79)26.47 (11.64 to 41.30)21.21 (7.26 to 35.16)
Week 866.67 (54.74 to 78.59)60.00 (47.60 to 72.40)56.25 (31.94 to 80.56)40.00 (15.21 to 64.79)38.24 (21.90 to 54.57)45.45 (28.47 to 62.44)
Week 1266.67 (54.74 to 78.59)75.00 (64.04 to 85.96)62.50 (38.78 to 86.22)60.00 (35.21 to 84.79)52.94 (36.16 to 69.72)45.45 (28.47 to 62.44)
Week 1683.05 (73.48 to 92.62)75.00 (64.04 to 85.96)62.50 (38.78 to 86.22)66.67 (42.81 to 90.52)50.00 (33.19 to 66.81)48.48 (31.43 to 65.54)
Week 2078.33 (67.91 to 88.76)81.67 (71.88 to 91.46)56.25 (31.94 to 80.56)60.00 (35.21 to 84.79)70.59 (55.27 to 85.90)72.73 (57.53 to 87.92)
Week 2881.67 (71.88 to 91.46)80.00 (69.88 to 90.12)68.75 (46.04 to 91.46)73.33 (50.95 to 95.71)73.53 (58.70 to 88.36)75.76 (61.14 to 90.38)
Week 3666.67 (54.74 to 78.59)75.00 (64.04 to 85.96)68.75 (46.04 to 91.46)80.00 (59.76 to 100.00)67.65 (51.92 to 83.37)84.85 (72.62 to 97.08)
Week 4466.67 (54.74 to 78.59)78.33 (67.91 to 88.76)56.25 (31.94 to 80.56)73.33 (50.95 to 95.71)58.82 (42.28 to 75.37)75.76 (61.14 to 90.38)
Week 5258.33 (45.86 to 70.81)70.00 (58.40 to 81.60)56.25 (31.94 to 80.56)66.67 (42.81 to 90.52)64.71 (48.64 to 80.77)66.67 (50.58 to 82.75)
SecondaryChange From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52

PASDAS is a composite psoriatic arthritis disease activity score that includes the following components: patient's global joint and skin assessment (visual analog scale in mm), physician's global psoriatic arthritis assessment (visual analog scale in mm), swollen (66 joints) and tender joint counts (68 joints), Leeds Enthesitis Index score, tender dactylitic digit score, physical component summary score (PCS) of Short Form 36 Health Survey and C-reactive protein (mg/L). Any missing component would result in PASDAS as missing. A higher PASDAS score indicates a higher disease activity.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52
Units on a scalePF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Week 4-1.22 ± 1.119-1.31 ± 1.090-0.94 ± 0.957-0.65 ± 0.653-0.56 ± 0.655-0.54 ± 0.897
Week 8-1.79 ± 1.295-1.65 ± 1.262-1.37 ± 1.127-1.14 ± 1.122-1.02 ± 0.988-0.67 ± 1.045
Week 12-2.10 ± 1.380-1.93 ± 1.278-1.67 ± 0.996-1.61 ± 1.106-1.04 ± 1.101-0.80 ± 1.158
Week 16-2.31 ± 1.302-2.20 ± 1.354-1.87 ± 1.024-2.18 ± 1.286-1.08 ± 1.127-0.90 ± 1.193
Week 20-2.48 ± 1.338-2.48 ± 1.474-2.49 ± 1.199-2.18 ± 1.441-2.37 ± 1.202-2.10 ± 1.367
Week 28-2.62 ± 1.354-2.60 ± 1.642-2.90 ± 1.279-3.18 ± 1.484-2.48 ± 1.181-2.81 ± 1.302
Week 36-2.73 ± 1.509-2.59 ± 1.644-3.08 ± 1.539-2.97 ± 1.550-2.69 ± 1.043-2.96 ± 1.425
Week 44-2.95 ± 1.421-2.85 ± 1.637-3.25 ± 0.819-3.23 ± 1.833-2.73 ± 1.157-3.23 ± 1.508
Week 52-3.03 ± 1.487-2.98 ± 1.568-3.36 ± 0.826-3.14 ± 1.461-2.84 ± 1.399-3.07 ± 1.775
SecondaryNumber of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) From Baseline (Day 1) Through Week 56 (All Causalities)

Treatment-emergent AEs are those with initial onset or that worsen in severity after the first dose of the study medication. All AEs in the table below were treatment-emergent AEs. An SAE is any untoward medical occurrence at any dose that: results in death; is life threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect; or that is considered to be an important medical event that may jeopardize the participant or may require intervention to prevent one of the other AE outcomes. Severe AEs were defined as AEs that interfered significantly with participant's usual function. Both SAEs and severe AEs were according to the investigator's assessment.

Time frame:
Baseline (Day 1) through Week 56
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) From Baseline (Day 1) Through Week 56 (All Causalities)
ParticipantsPF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Participants with AEs464510102425
Participants with SAEs180012
Participants with severe AEs160012
Participants with dose reduction or temporary discontinuation due to AEs18144348
SecondaryNumber of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) From Baseline (Day 1) Through Week 56 (Treatment-related)

Treatment-emergent AEs are those with initial onset or that worsen in severity after the first dose of the study medication. All AEs in the table below were treatment-emergent AEs. An SAE is any untoward medical occurrence at any dose that: results in death; is life threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect; or that is considered to be an important medical event that may jeopardize the participant or may require intervention to prevent one of the other AE outcomes. Severe AEs were defined as AEs that interfered significantly with participant's usual function. Both SAEs and severe AEs were according to the investigator's assessment. Treatment-related AEs were also determined by the investigator.

Time frame:
Baseline (Day 1) through Week 56
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) From Baseline (Day 1) Through Week 56 (Treatment-related)
ParticipantsPF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Participants with AEs1715621110
Participants with SAEs010011
Participants with severe AEs010011
Participants with dose reduction or temporary discontinuation due to AEs854113
SecondaryNumber of Participants Who Discontinued From Study Due to Treatment-emergent AEs From Baseline (Day 1) Through Week 56

An AE is any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of the study medication.

Time frame:
Baseline (Day 1) through Week 56
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued From Study Due to Treatment-emergent AEs From Baseline (Day 1) Through Week 56
ParticipantsPF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Otitis media acute010000
Upper respiratory tract infection000001
Psoriasis000001

Adverse events

Collected over From the time the participants received the study treatment up to 28 days after the last treatment administration (approximately 56 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-06700841 60 mg QD -> PF-06700841 60 mg QD0/60 (0%)1/60 (1.7%)37/60 (61.7%)
PF-06700841 30 mg QD -> PF-06700841 30 mg QD0/60 (0%)8/60 (13.3%)34/60 (56.7%)
PF-06700841 10 mg QD -> PF-06700841 60 mg QD0/16 (0%)0/16 (0%)10/16 (62.5%)
PF-06700841 10 mg QD -> PF-06700841 30 mg QD0/15 (0%)0/15 (0%)10/15 (66.7%)
Placebo -> PF-06700841 60 mg QD0/34 (0%)1/34 (2.9%)18/34 (52.9%)
Placebo -> PF-06700841 30 mg QD0/33 (0%)2/33 (6.1%)20/33 (60.6%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
Pneumonia viralInfections and infestations0/600/600/160/150/341/33
PsoriasisSkin and subcutaneous tissue disorders0/600/600/160/150/341/33
COVID-19 pneumoniaInfections and infestations0/600/600/160/151/340/33
Duodenal ulcerGastrointestinal disorders1/600/600/160/150/340/33
Cholecystitis chronicHepatobiliary disorders1/600/600/160/150/340/33
AppendicitisInfections and infestations0/601/600/160/150/340/33
Otitis media acuteInfections and infestations0/601/600/160/150/340/33
PneumoniaInfections and infestations0/601/600/160/150/340/33
VaricellaInfections and infestations0/601/600/160/150/340/33
Radius fractureInjury, poisoning and procedural complications0/601/600/160/150/340/33
Most frequent other events
Showing 10 of 44
Most frequent other events
EventPF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QD
BronchitisInfections and infestations4/600/601/162/151/341/33
NasopharyngitisInfections and infestations8/605/600/162/151/344/33
HeadacheNervous system disorders5/604/602/161/151/343/33
Upper respiratory tract infectionInfections and infestations7/605/600/160/152/343/33
Alanine aminotransferase increasedInvestigations5/607/601/161/152/340/33
AnaemiaBlood and lymphatic system disorders2/602/600/160/153/341/33
NauseaGastrointestinal disorders4/601/600/160/153/341/33
HypertensionVascular disorders5/602/601/160/151/341/33
LeukopeniaBlood and lymphatic system disorders1/600/600/161/150/340/33
NeutropeniaBlood and lymphatic system disorders3/600/600/161/151/340/33

Baseline characteristics

Baseline analysis population included all participants who were randomized to the study and received at least one dose of the randomized study treatment.

Age, Continuous
Age, Continuous(Years)PF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QDTotal
Mean48.7 ± 11.4745.9 ± 10.2347.8 ± 14.1647.7 ± 12.9547.9 ± 12.5848.5 ± 11.8447.6 ± 11.62
Age, Continuous
Age, Continuous(Years)PF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QDTotal
Median50.0 (24 to 70)46.0 (26 to 73)43.5 (22 to 71)47.0 (28 to 73)48.0 (21 to 69)50.0 (23 to 72)48.0 (21 to 73)
Age, Customized
Age, Customized(Participants)PF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QDTotal
18-44222696131490
45-643531581716112
≥6533214316
Sex: Female, Male
Sex: Female, Male(Participants)PF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QDTotal
Female3432772016116
Male2628981417102
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QDTotal
White596016153433217
Asian1000001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PF-06700841 60 mg QD -> PF-06700841 60 mg QDPF-06700841 30 mg QD -> PF-06700841 30 mg QDPF-06700841 10 mg QD -> PF-06700841 60 mg QDPF-06700841 10 mg QD -> PF-06700841 30 mg QDPlacebo -> PF-06700841 60 mg QDPlacebo -> PF-06700841 30 mg QDTotal
Not Hispanic or Latino605916153332215
Not reported0100113
08

Study locations

48 sites
  • Rheumatology Research Unit
    Maroochydore, Queensland 4558, Australia
  • Emeritus Research
    Melbourne, Victoria 3124, Australia
  • MHAT Trimontium OOD
    Plovdiv, 4000, Bulgaria
  • University Multiprofile Hospital for Active Treatment "Pulmed"
    Plovdiv, 4002, Bulgaria
  • University Multiprofile Hospital for Active Treatment ''Plovdiv'' AD
    Plovdiv, 4027, Bulgaria
  • Medical Center "Pirogov"
    Sofia, 1000, Bulgaria
  • "Diagnostic-Consulting Center XVII - Sofia"
    Sofia, 1505, Bulgaria
  • University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski
    Sofia, 1612, Bulgaria
  • L.K.N. Arthrocentrum s.r.o.
    Hlucin, 748 01, Czechia
  • CCR Czech a.s.
    Pardubice, 530 02, Czechia
  • Revmatologicky ustav
    Praha 2, 128 50, Czechia
  • CCR Prague s.r.o.
    Praha 3, 130 00, Czechia
  • MEDICAL PLUS s.r.o.
    Uherske Hradiste, 68601, Czechia
  • Innomedica OU
    Tallinn, 10117, Estonia
  • Center for Clinical and Basic Research
    Tallinn, 10128, Estonia
  • East Tallinn Central Hospital
    Tallinn, 11312, Estonia
  • Qualiclinic Kft.
    Budapest, 1036, Hungary
  • VITAL MEDICAL CENTER Orvosi es Fogorvosi Kozpont
    Veszprem, 8200, Hungary
  • Hospital of Lithuanian University of Health Sciences, Kauno klinikos
    Kaunas, LT-50161, Lithuania
  • National Osteoporosis Center
    Vilnius, LT-09310, Lithuania
  • ZDROWIE Osteo-Medic s.c. L. I A. Racewicz, A. i J. Supronik
    Bialystok, 15-351, Poland
  • ClinicMed Daniluk Nowak Sp. Jawna
    Bialystok, 15-879, Poland
  • Zespol Poradni Specjalistycznych "REUMED" Filia nr 2
    Lublin, 20-582, Poland
  • NZOZ Lecznica Mak-Med s.c.
    Nadarzyn, 05-830, Poland
  • Twoja Przychodnia - Centrum Medyczne Nowa Sol
    Nowa Sol, 67-100, Poland
  • Ai Centrum Medyczne Sp. z o.o. Sp. k.
    Poznan, 61-113, Poland
  • Prywatna Praktyka Lekarska Prof. UM dr hab. med. Pawel Hrycaj
    Poznan, 61-397, Poland
  • RCMed Oddzial Sochaczew
    Sochaczew, 96-500, Poland
  • NASZ LEKARZ Przychodnie Medyczne
    Torun, 87-100, Poland
  • REUMATIKA - Centrum Reumatologii NZOZ
    Warszawa, 02-691, Poland
  • LLC "Family Outpatient clinic #4"
    Korolev, Moscow Region 141060, Russian Federation
  • FGBOU VO "Orenburg State Medical University" of the Ministry of Health of the Russian Federation
    Orenburg, 460000, Russian Federation
  • GBUZ "Orenburg Regional Clinical Hospital"
    Orenburg, 460018, Russian Federation
  • SBHI of the Republic of Karelia "Republican Hospital n. a. V.A. Baranov"
    Petrozavodsk, 185910, Russian Federation
  • FSBEI of HE "Ryazan State Medical University n. a academician I.P.Pavlov"
    Ryazan, 390026, Russian Federation
  • SBI of Ryazan Region "Regional Clinical Hospital"
    Ryazan, 390039, Russian Federation
  • Limited Liability Company "Sanavita"
    Saint Petersburg, 195257, Russian Federation
  • GUZ "Regional Clinical Hospital"
    Saratov, 410053, Russian Federation
  • LLC "BioMed"
    Vladimir, 600005, Russian Federation
  • State Autonomous Healthcare Institution of Yaroslavl Region
    Yaroslavl, 150003, Russian Federation
  • Institute of Rheumatology
    Belgrade, 11000, Serbia
  • Institute for Treatment and Rehabilitation Niska Banja
    Niska Banja, 18205, Serbia
  • Narodny ustav reumatickych chorob
    Piestany, 921 12, Slovakia
  • MUDr. Zuzana Cizmarikova, s.r.o.
    Poprad, 058 01, Slovakia
  • REUMEX s.r.o.
    Rimavska Sobota, 979 01, Slovakia
  • Complejo Hospitalario Universitario de Santiago de Compostela
    Santiago de Compostela, A Coruna 15706, Spain
  • Hospital Universitario A Coruna
    A Coruna, 15006, Spain
  • Hospital Quironsalud Infanta Luisa
    Sevilla, 41010, Spain
09

References and documents

Publications

  • Banfield C, Scaramozza M, Zhang W, Kieras E, Page KM, Fensome A, Vincent M, Dowty ME, Goteti K, Winkle PJ, Peeva E. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis. J Clin Pharmacol. 2018 Apr;58(4):434-447. doi: 10.1002/jcph.1046. Epub 2017 Dec 21. PubMed 29266308 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Apr 2020, 9 months.

Results were first posted in Aug 2021, 1 year 3 months after primary completion. A results delay was requested in Nov 2020.

Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2019
First posted
May 24, 2019
StartActual
Jun 13, 2019
Primary completionActual
Apr 6, 2020
CompletionActual
Jan 15, 2021
Results delay requested
Nov 12, 2020
Results first posted
Aug 4, 2021
Last update
Aug 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03963401
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 24, 2019
Start date
Jun 13, 2019
Primary completion
Apr 6, 2020
Completion
Jan 15, 2021
Results posted
Aug 4, 2021
Last update
Aug 4, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06700841

Start the discussion